logo

For the Inventor, By the Inventor

New York, NY, United States of America

Xingxing Zang

LinkedIn

This inventor holds 13 USPTO granted patents and 12 published patent applications. Top assignees: Albert Einstein College of Medicine, Sloan-Kettering Institute for Cancer Research, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xingxing Zang. Retrieved from https://idiyas.com/inventor/xingxing-zang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 

% Patents Active = 100.0

Average Co-Inventor Count = 1.5

ph-index = 1

Forward Citations = 12(Granted Patents)


Company Filing History:

goldMedal12 out of 513 
 
Albert Einstein College of Medicine
 patents
silverMedal2 out of 519 
 
Sloan-Kettering Institute for Cancer Research
 patents
bronzeMedal1 out of 3,693 
 
The United States of America, as Represented by the Secretary, Department of Health and Human Services
 patents
where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...
13 patents (USPTO):Explore Patents
1. 12534527 - KIR3DL3 IS AN INHIBITORY RECEPTOR OF THE IMMUNE SYSTEM AND USES THEREOF (2026-01-27),
2. 12263203 - BTNL9 and ERMAP as novel inhibitors of the immune system for immunotherapies (2025-04-01),
3. 12252538 - Monoclonal antibodies against IgV domain of B7-H3 and uses thereof (2025-03-18),
4. 12221489 - Antibodies to human B7x for treatment of metastatic cancer (2025-02-11),
5. 12145989 - Antagonist antibodies against human immune checkpoint CEACAM1 (CD66a) and formulations, kits, and methods of use thereof (2024-11-19),
6. 12134645 - Monoclonal antibodies against human tim-3 (2024-11-05),
7. 11377494 - Antagonist antibodies against human immune checkpoint CEACAM1 (CD66a) and formulations, kits, and methods of use thereof (2022-07-05),
8. 11261253 - HHLA2 as a novel inhibitor of human immune system and uses thereof (2022-03-01),
9. 10882893 - TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies (2021-01-05),
10. 10689432 - B7X and its derivatives for treating and preventing cardiovascular disease (2020-06-23),
11. 10280208 - TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies (2019-05-07),
12. 10093737 - HHLA2 as a novel inhibitor of human immune system and uses thereof (2018-10-09),
13. 9447186 - Antibodies to human B7x for treatment of metastatic cancer (2016-09-20),

Title: The Innovative Contributions of Xingxing Zang

Introduction

Xingxing Zang is a prominent inventor based in New York, NY (US), known for his significant contributions to the field of immunotherapy. With a total of 12 patents to his name, Zang has made remarkable strides in developing novel treatments for cancer and other diseases.

Latest Patents

Among his latest patents are BTNL9 and ERMAP, which serve as novel inhibitors of the immune system for immunotherapies. These patents provide methods for treating tumors in subjects using BTNL9-binding and ERMAP-binding antibodies. Additionally, Zang has developed a fusion protein comprising BTNL9 or ERMAP, along with related compositions and encoding nucleic acids. Another notable patent involves monoclonal antibodies that target the IgV domain of B7-H3, offering methods for treating cancer and infections, as well as imaging B7-H3 positive cells.

Career Highlights

Zang has worked at prestigious institutions such as the Albert Einstein College of Medicine and the Sloan Kettering Institute for Cancer Research. His work in these organizations has allowed him to advance his research and contribute to groundbreaking discoveries in cancer treatment.

Collaborations

Zang has collaborated with notable figures in the field, including James P. Allison and Jordan M. Chinai. These partnerships have further enhanced his research and innovation in immunotherapy.

Conclusion

Xingxing Zang's innovative work and numerous patents highlight his dedication to advancing medical science, particularly in the realm of cancer treatment. His contributions continue to pave the way for new therapeutic approaches that could significantly impact patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…